Entrovas 49 mg+51 mg (Tablet)
Unit Price: ৳ 85.00 (2 x 10: ৳ 1,700.00)
Strip Price: ৳ 850.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Sacubitril valsartan |
| Company | Renata limited |
| Also available as |
Product Title
- Heart Failure Tablet
Category
- Cardiovascular Medicine
- Pediatric Medicine
Description
- This tablet is indicated for reducing the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- It is also used for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- The tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. It inhibits neprilysin (NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects are attributed to the increased levels of peptides that are degraded by neprilysin and the simultaneous inhibition of the effects of angiotensin II by valsartan.
- The recommended starting dose for adult heart failure is 49/51 mg orally twice daily, which can be doubled after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient. The recommended dose for pediatric patients aged one year and older varies based on weight categories and requires adjustments every 2 weeks.
- The tablet comes with precautions and warnings regarding angioedema, hypotension, impaired renal function, hyperkalemia, and a risk of interaction with other medications like renin-angiotensin-aldosterone system blockers, potassium-sparing diuretics, NSAIDs, and lithium.
- It is contraindicated in patients with hypersensitivity to any component, a history of angioedema related to previous ACE inhibitor or ARB therapy, and in combination with ACE inhibitors or aliskiren in patients with diabetes.
- The most common side effects include angioedema, hypotension, impaired renal function, hyperkalemia, and cough.
- The tablet should be stored in a dry place below 30°C, protected from moisture and out of the reach of children.
Dosage & Administration
- Recommended starting dose for adult heart failure: 49/51 mg orally twice daily
- Recommended maintenance dose for adult heart failure: 97/103 mg twice daily
- Pediatric patients aged one year and older require dose adjustments based on weight categories every 2 weeks
Interaction
- Dual blockade of the renin-angiotensin-aldosterone system should be avoided
- Potassium-sparing diuretics may increase serum potassium levels
- NSAIDs may increase the risk of renal impairment
- Lithium may increase the risk of lithium toxicity
Contraindications
- Hypersensitivity to any component
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors, aliskiren in patients with diabetes, and within 36 hours of switching from or to an ACE inhibitor
Side Effects
- Angioedema
- Hypotension
- Impaired Renal Function
- Hyperkalemia
- Cough
Pregnancy & Lactation
- Safety and effectiveness have not been established in pediatric patients less than 1 year of age
- No relevant pharmacokinetic differences observed in elderly patients compared to the overall population
- No dose adjustment required for mild hepatic impairment
- Not recommended in patients with severe hepatic impairment
- No dose adjustment required in patients with mild to moderate renal impairment
- Recommended starting dose in patients with severe renal impairment: 24/26 mg twice daily
Precautions & Warnings
- May cause angioedema
- May lower blood pressure and cause symptomatic hypotension
- Requires monitoring of serum creatinine, potassium levels, and renal function in certain patient populations
- Dosage reduction or interruption may be required in patients with risk factors for hyperkalemia
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- No relevant pharmacokinetic differences observed in elderly patients compared to the overall population
- Starting dose adjustment recommended for patients with severe renal or hepatic impairment
Overdose Effects
- Limited data available on overdosage in human subjects
- Hypotension is the most likely result of overdosage
- Symptomatic treatment should be provided
- Unlikely to be removed by hemodialysis due to high protein binding
Storage Conditions
- Keep in a dry place below 30°C
- Protect from moisture
- Keep out of the reach of children